- Home
- Publications
- Publication Search
- Publication Details
Title
Nintedanib in NSCLC: evidence to date and place in therapy
Authors
Keywords
-
Journal
Therapeutic Advances in Medical Oncology
Volume 8, Issue 3, Pages 188-197
Publisher
SAGE Publications
Online
2016-02-18
DOI
10.1177/1758834016630976
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 143TiP * SPECTALUNG: SCREENING PATIENTS WITH THORACIC TUMORS FOR EFFICIENT CLINICAL TRIAL ACCESS
- (2015) B. Besse et al. ANNALS OF ONCOLOGY
- Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non–Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials
- (2015) Claire L. Vale et al. Clinical Lung Cancer
- Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer
- (2015) Silvia Novello et al. EUROPEAN JOURNAL OF CANCER
- Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?
- (2015) Francesco Passiglia et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Nintedanib: From Discovery to the Clinic
- (2015) Gerald J. Roth et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non–Small-Cell Lung Cancer
- (2015) Isamu Okamoto et al. Journal of Thoracic Oncology
- Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel
- (2015) Martin Reck et al. LUNG CANCER
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Anti-angiogenesis in Non-small-cell Lung Cancer: an Update
- (2015) Liza C. Villaruz et al. Current Oncology Reports
- Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120)
- (2015) Ruby Yun-Ju Huang et al. Oncotarget
- Targeting Angiogenesis in Squamous Non-Small Cell Lung Cancer
- (2014) Bilal Piperdi et al. DRUGS
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
- (2014) Martin Reck et al. LANCET ONCOLOGY
- Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: A meta-analysis of randomized controlled clinical trials
- (2014) Ning Zhao et al. LUNG CANCER
- Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer
- (2014) Ning Li et al. PLoS One
- Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
- (2013) Giuseppe Bronte et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer
- (2013) Christian Rolfo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2013) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer
- (2013) B. Kutluk Cenik et al. MOLECULAR CANCER THERAPEUTICS
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) S. Peters et al. ANNALS OF ONCOLOGY
- A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer
- (2012) R. C. Doebele et al. ANNALS OF ONCOLOGY
- Targeting tumor neovasculature in non-small-cell lung cancer
- (2012) Athanasios G. Pallis et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer
- (2012) Luis G. Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1
- (2012) Giorgio V. Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial
- (2012) Giorgio V. Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis
- (2012) Ariel Lopez-Chavez et al. Journal of Thoracic Oncology
- Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Richard H. de Boer et al. JOURNAL OF CLINICAL ONCOLOGY
- Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma
- (2010) Giuseppe Bronte et al. CANCER TREATMENT REVIEWS
- Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients
- (2010) P. M. Ellis et al. CLINICAL CANCER RESEARCH
- HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer
- (2010) Autumn L Jackson et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer
- (2010) Giorgio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
- (2010) Roy S Herbst et al. LANCET ONCOLOGY
- Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors
- (2009) K. Mross et al. CLINICAL CANCER RESEARCH
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation